Consistent with previous studies23–25, targeting SOAT1 suppresses tumor growth in HCC using CCK8 assay and western blot analysis (Fig. 4A–C), but the metabolic alteration response to SOAT1-targeted therapy, which might contribute to exploring new approaches that enhance the cytotoxicity of avasimibe in HCC, is little known. The gene discussed is SOAT1; the disease is hepatocellular carcinoma.